Novartis AG (NVS)
NYSE: NVS · Real-Time Price · USD
135.03
-0.16 (-0.12%)
At close: Dec 16, 2025, 4:00 PM EST
133.85
-1.18 (-0.87%)
After-hours: Dec 16, 2025, 7:07 PM EST
Novartis AG Employees
Novartis AG had 75,883 employees as of December 31, 2024. The number of employees decreased by 174 or -0.23% compared to the previous year.
Employees
75,883
Change (1Y)
-174
Growth (1Y)
-0.23%
Revenue / Employee
$742,880
Profits / Employee
$189,674
Market Cap
259.57B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 75,883 | -174 | -0.23% |
| Dec 31, 2023 | 76,057 | -25,646 | -25.22% |
| Dec 31, 2022 | 101,703 | -2,620 | -2.51% |
| Dec 31, 2021 | 104,323 | -1,471 | -1.39% |
| Dec 31, 2020 | 105,794 | 1,880 | 1.81% |
| Dec 31, 2019 | 103,914 | -21,247 | -16.98% |
| Dec 31, 2018 | 125,161 | 3,564 | 2.93% |
| Dec 31, 2017 | 121,597 | 3,204 | 2.71% |
| Dec 31, 2016 | 118,393 | -307 | -0.26% |
| Dec 31, 2015 | 118,700 | -14,713 | -11.03% |
| Dec 31, 2014 | 133,413 | -2,283 | -1.68% |
| Dec 31, 2013 | 135,696 | 7,972 | 6.24% |
| Dec 31, 2012 | 127,724 | 4,038 | 3.26% |
| Dec 31, 2011 | 123,686 | 4,268 | 3.57% |
| Dec 31, 2010 | 119,418 | 19,584 | 19.62% |
| Dec 31, 2009 | 99,834 | 3,117 | 3.22% |
| Dec 31, 2008 | 96,717 | -1,483 | -1.51% |
| Dec 31, 2007 | 98,200 | -2,535 | -2.52% |
| Dec 31, 2006 | 100,735 | 9,735 | 10.70% |
| Dec 31, 2005 | 91,000 | 9,600 | 11.79% |
| Dec 31, 2004 | 81,400 | 2,859 | 3.64% |
| Dec 31, 2003 | 78,541 | 5,664 | 7.77% |
| Dec 31, 2002 | 72,877 | 2,557 | 3.64% |
| Dec 31, 2001 | 70,320 | 1,252 | 1.81% |
| Dec 31, 2000 | 69,068 | -13,391 | -16.24% |
| Dec 31, 1999 | 82,459 | -3,376 | -3.93% |
| Dec 31, 1998 | 85,835 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
NVS News
- 4 days ago - Novartis breaks ground on flagship manufacturing hub in North Carolina - GlobeNewsWire
- 7 days ago - Novartis' Investigational Drug Reports Longer Disease Control In Patients With Rare Blood Disorder - Benzinga
- 7 days ago - Tiny Biotech Terns Takes Aim At Novartis' Leukemia Blockbuster - Benzinga
- 7 days ago - Novartis ianalumab significantly extends disease control in patients with immune thrombocytopenia with only four once-monthly doses - GlobeNewsWire
- 7 days ago - 1 in 4 metastatic breast cancer patients treated with Novartis Kisqali® remain progression-free beyond 4 years - GlobeNewsWire
- 7 days ago - Relation announces strategic collaboration with Novartis to advance therapeutics for atopic diseases - GlobeNewsWire
- 15 days ago - Novartis AG (NVS) Discusses Social Impact, Global Health Initiatives, and Sustainability Strategy Transcript - Seeking Alpha
- 21 days ago - Why Novartis Stock Topped the Market Today - The Motley Fool